Drugs

Nov 8, 2024, 18:35

Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

Erman Akkus shared a post on X:

”Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity?

HR: 0.91 (95% CI 0.73–1.14) In patients with a history of CVD?

HR: 0.81 (95% CI 0.58–1.15)”

Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data

Authors: Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye.

Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

aromatase inhibitor Bent Ejlertsen Breast Cancer cancer Denmark Erman Akkus Giulia Corn ischaemic cardiotoxicity Jan Wohlfahrt Kim Dalhoff Lars Køber Mads Melbye Maj-Britt Jensen Marie Lund OncoDaily Oncology postmenopausal patients The Lancet Oncology Tonny Petersen

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage